Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Metrics to compare | TLSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTLSAPeersSector | |
---|---|---|---|---|
P/E Ratio | −16.8x | −2.7x | −0.6x | |
PEG Ratio | −0.48 | −0.04 | 0.00 | |
Price/Book | 50.6x | 2.4x | 2.6x | |
Price / LTM Sales | - | 8.5x | 3.3x | |
Upside (Analyst Target) | 334.6% | 239.9% | 39.1% | |
Fair Value Upside | Unlock | 16.9% | 5.4% | Unlock |